Skip to main content
. 2021 Dec 7;601(7894):623–629. doi: 10.1038/s41586-021-04278-5

Fig. 1. Overview of the study design.

Fig. 1

Pre-therapy breast tumours from 168 patients were profiled using DNA sequencing and RNA sequencing (RNA-seq) and digital pathology analysis. Response was assessed on completion of neoadjuvant therapy using the RCB classification. Individual pre-therapy clinical, molecular and digital pathology features associated with pCR were identified and integrated within machine learning models to predict responses, which were then validated in an independent dataset. sWGS, shallow whole-genome sequencing; WES, whole-exome sequencing.